Diagnostic value of GeneXpert MTB/RIF in bronchoalveolar lavage fluid for pulmonary non-tuberculosis mycobacterial in acid-fast stain smear-positive and GeneXpert MTB/RIF-negative cases.

The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested real-time fluorescence quantitative nucleic acid amplification detection technology [Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF)] in bronchoalveolar lavage fluid (BALF) acid-fast smear-positive cases. Between 1 January 2017 and 30 June 2022, 365 patients who underwent fibreoptic bronchoscopy and had positive acid-fast smears of BALF were examined using Xpert MTB/RIF. The mycobacteria growth indicator tube (MGIT) 960 was used for rapid sputum culture and traditional drug sensitivity testing. Combined with mycobacterial culture and drug sensitivity results, Xpert results of alveolar lavage fluid were analysed to guide diagnosis and treatment. The sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of Xpert detection for diagnosing NTM lung disease in acid-fast smear-positive cases were 100% (45/45), 99.68% (310/311), 97.83% (45/46) and 100% (310/310), respectively. Xpert MTB/RIF in alveolar lavage fluid can not only detect RIF resistance but also distinguish pulmonary TB from NTM pulmonary disease in patients with positive acid-fast smears.